Novartis

More than 750 Million Anti Malaria Treatments for Adults and Children Provided Without Profit

Malaria is still one of the most deadly diseases in developing countries
Article

Today is World Malaria Day. Malaria is preventable and curable, yet it is still one of the most deadly diseases in developing countries. Despite extraordinary progress in the fight against malaria over the last 15 years, the disease still claims the life of a child every two minutes.

Experts Discuss Better Treatments Against Parasitic Diseases

The Novartis Institute for Tropical Diseases convenes parasitology experts in Zambia
Article

On April 4-8 2016, the Novartis Institute for Tropical Diseases (NITD) held a Symposium on Parasitology in Lusaka, Zambia, bringing together international and local experts in the field with the aim of engaging in productive scientific exchange on parasitic diseases - including malaria, sleeping sickness (Human African Trypanosomiasis), Chagas, leishmaniasis, and cryptosporidiosis.

Novartis and Red Cross Partner to Tackle Chronic Diseases in Refugee Populations

Novartis will provide medicines for high blood pressure and diabetes
Article

Syrian refugees in Lebanon suffering from chronic diseases face difficulties accessing diagnosis, medicines and ongoing care. The International Committee of the Red Cross (ICRC) and Novartis are partnering to improve care and treatment for the most vulnerable population in Lebanon. The objective is to establish a blueprint for improving diagnosis, treatment and follow-up for refugees, as well as members of their Lebanese host families, who suffer from chronic diseases. 

First Novartis Access Treatments Delivered to Kenya

Shipment includes medicines against cardiovascular diseases, diabetes, respiratory conditions and breast cancer
Article

We are pleased to announce that the first Novartis Access shipment has just been delivered to Kenya. This shipment includes medicines against cardiovascular diseases, diabetes, respiratory conditions and breast cancer. The medicines are currently stored in the MEDS warehouse (Mission for Essential Drugs and Supplies) in Nairobi. MEDS is a faith-based not-for-profit medical supply chain and capacity building organization in Kenya.

Novartis Foundation Commemorates World Leprosy Day with its Continued Efforts to go the Last Mile Toward Elimination

2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease
Summary: 
  • 2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease

  • New strategy from the Novartis Foundation to accelerate elimination is focused on interrupting transmission of the disease

  • Last year Novartis renewed its commitment with the WHO to donate multidrug therapy to treat leprosy through the year 2020

  • More than 200,000 people are diagnosed with leprosy every year; approximately 10% of those are children, indicating continued spread of the disease
Press Release
  • 2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease

  • New strategy from the Novartis Foundation to accelerate elimination is focused on interrupting transmission of the disease

  • Last year Novartis renewed its commitment with the WHO to donate multidrug therapy to treat leprosy through the year 2020

  • More than 200,000 people are diagnosed with leprosy every year; approximately 10% of those are children, indicating continued spread of the disease

Novartis Releases 2015 Corporate Responsibility Performance Report

Article

Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthcare industry. In addition, the publication of the CR report now coincides with the Novartis Annual Report, providing a more integrated view on the company’s performance.

The Novartis Foundation and the London School of Hygiene & Tropical Medicine Join Forces to Put Hypertension Care and Management on the Global Health Agenda

Press Release
  • Global Health and hypertension community gather to highlight innovative delivery models for hypertension management in low- and middle-income countries
  • Experts at London-based dialogue event will also focus on potential enablers to scale healthcare delivery models and critical need for evidence generation
  • Deaths from hypertension are estimated at 9.4 million people annually globally, which is equivalent to all infectious diseases combined

Novartis Foundation and Partners Launch New Hypertension Program in Ghana

Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control
Press Release
  • Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control
     
  • Screening and treatment is shifted to the community and technology supports healthcare workers and empowers patient self-management
     
  • More than one quarter of the adult population in Ghana has hypertension, but only 4% of these hypertensive patients have it under control
     

Expanding Access to Affordable Treatments Against Chronic Diseases

Novartis Access hosts second stakeholder dialogue
Article

On May 25, Novartis Access held its second stakeholder dialogue in conjunction with the 2016 World Health Assembly to share first learnings from the Kenya launch, and to continue the discussion on how to address the burden of noncommunicable diseases (NCDs) in lower-income countries. This event is part of the company’s public commitment to transparency and open dialogue with stakeholders as Novartis Access is rolled out.

Kenya First Country to Launch ‘Novartis Access’, Expanding Affordable Treatment Options Against Chronic Diseases

Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country
Summary: 

•    Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries
•    Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country1
•    Agreements signed with Kenyan government and NGOs include programs to distribute medicines, raise disease awareness and strengthen healthcare system capabilities in key NCDs 

Press Release

•    Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries
•    Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country1
•    Agreements signed with Kenyan government and NGOs include programs to distribute medicines, raise disease awareness and strengthen healthcare system capabilities in key NCDs 

Pages

Subscribe to Novartis